🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

As we promote Ontario's #LifeSciences BIO Convention check out the #Top10 #biotech companies to watch in 2023: Cyclica, Deep Genomics, Microbix, bio.., ProteinQure, Roche, Sanofi, Triumvira Immunologics & Verv: investontario.ca/spotlights/top… #BIO2023

Thanks to all the BioHive folks who showed up to support the #SLC #LGBTQ+ community at #Pride this weekend! We had a ton of fun walking in the parade — we’re already looking forward to next year. 🏳️‍🌈❤️

We are honoured to have been listed as one of the 'Top Ontario biotech companies to watch in 2023' by Invest Ontario! As we enter into a new chapter of #drugdiscovery as Recursion, we are committed to continuing our work in advancing the #AI healthcare ecosystem in

We’re thrilled to congratulate our Board Chairperson, R. Martin Chavez, on his recognition as a #biopharma leader paving the way for #LGBTQ+ #scientists, patients, #entrepreneurs & C-suites by Endpoints News. Learn more about Martin: bit.ly/3ClDhqB

On the tails of acquiring Cyclica and Valence Labs this past month, co-founder & #CEO Chris Gibson spoke with Clinical Leader to share more about the agreements, the rapidly changing #techbio space, our commitment to patients and more. Read: bit.ly/3OX5trz #ai #ml

Great segment from Squawk Box about #AI in #drugdiscovery this morning! Thanks to Scott Gottlieb, MD 🇺🇸 for including us in the conversation. Watch ⬇️ #biotech #techbio

We’re excited to announce we have successfully predicted the protein target for every molecule in our compound library using Cyclica’s technology! That’s >1M compounds profiled in a matter of weeks since closing the acquisition, with a merged dataset leading us to many new

Today we announced that our Phase 2 trial of REC-994 for the potential treatment of Cerebral Cavernous Malformations (#CCM) has reached full enrollment. Learn more: ir.recursion.com/news-releases/…

Co-founder & CEO Chris Gibson spoke with nature about our approach to applying #ai and #machinelearning in cellular imaging to decode #biology. Read the story to learn more: go.nature.com/43iqpxn #biotech #techbio

🆕Hot off the press! This paper from Levon in collaboration with Recursion is a great example of how AI-enabled virtual screening methods can accelerate drug discovery efforts. Read how they identified ligands for the DCAF1 WDR domain: bit.ly/3CHF75k

It's been a fantastic morning celebrating the official opening of our #Toronto office alongside members of Canada's #techbio community. We're thrilled to be placing roots in this vibrant and welcoming tech & research hub. Thanks to Hon. Sean Fraser, Premier Doug Ford, Hon.

Appreciated attending the opening of Recursion Canada’s HQ in Toronto. Congrats to dear friend Naheed Kurji (he/him) on his leadership of Cyclica & new role at Recursion. Thx to Recursion for choosing to invest in Toronto. No better place to find talent in AI & life sciences.

It’s that time of the year again — Recursion Summer Break! Every year over the holidays & 4th of July week, we close the office to rest and recharge. We’ll be back from our company-wide break on Monday, July 10th! #outsideRecursion #summerbreak #OOO

Great to see this informative article from Chemical & Engineering News (C&EN (Chemical & Engineering News)) about how #AI-derived breakthroughs in drug #research are spurring change across the pharmaceutical industry. We are proud to see it feature Recursion, our partner Genentech, our acquisitions

Today we announced a collaboration and $50 million investment from NVIDIA to accelerate our groundbreaking foundation models in AI-enabled drug discovery. Read the press release: ir.recursion.com/news-releases/… Read the blog from our CTO Ben Mabey: recursion.com/news/recursion…

#ICYMI - Our #CTO, Ben Mabey (Ben Mabey), wrote a #blog that takes a deep dive into our recent NVIDIA collaboration & how it marks a significant milestone on our journey toward revolutionizing #drugdiscovery through #AI. Read it here: bit.ly/44pFy0y #nvidia $NVDA

With the unveiling of Valence Labs (Valence Labs), our new #ML research center, we are doubling down on our commitment to open science by dedicating this team to building the ML community through data, tool and infrastructure releases. And we are kicking things off by committing

#BREAKING: We bridged the protein and chemical space by predicting the protein target(s) for ~36 billion compounds in the Enamine Ltd 🇺🇦 REAL Space using NVIDIA’s DGX Cloud and our own NVIDIA-based supercomputer, BioHive-1. Learn more: ir.recursion.com/news-releases/… (1/3)

Predicting protein targets for ~36 billion compounds takes a massive team effort. We sat down with our VP of #digitalchemistry Stephen MacKinnon to learn more about what went into accomplishing this feat. Read more: recursion.com/news/a-deep-di… #biotech #artificialintelligence